These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17432221)
41. Potential therapeutic agents against Alzheimer's disease from natural sources. Park SY Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936 [TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors. Guo T; Gu H; Hobbs DW; Rokosz LL; Stauffer TM; Jacob B; Clader JW Bioorg Med Chem Lett; 2007 Jun; 17(11):3010-3. PubMed ID: 17418571 [TBL] [Abstract][Full Text] [Related]
43. [Secretases as therapeutic targets for the treatment of Alzheimer's disease]. Dejaegere T; de Strooper B Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081 [TBL] [Abstract][Full Text] [Related]
45. Presenilin diversifies its portfolio. Parks AL; Curtis D Trends Genet; 2007 Mar; 23(3):140-50. PubMed ID: 17280736 [TBL] [Abstract][Full Text] [Related]
46. gamma-secretases: from cell biology to therapeutic strategies. Bergmans BA; De Strooper B Lancet Neurol; 2010 Feb; 9(2):215-26. PubMed ID: 20129170 [TBL] [Abstract][Full Text] [Related]
47. Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease. Mal S; Malik U; Pal D; Mishra A Curr Drug Targets; 2021; 22(12):1376-1403. PubMed ID: 33390127 [TBL] [Abstract][Full Text] [Related]
48. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients? Ross JS; Imbimbo BP J Alzheimers Dis; 2010; 22(2):401-4. PubMed ID: 21149978 [TBL] [Abstract][Full Text] [Related]
49. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Kukar T; Murphy MP; Eriksen JL; Sagi SA; Weggen S; Smith TE; Ladd T; Khan MA; Kache R; Beard J; Dodson M; Merit S; Ozols VV; Anastasiadis PZ; Das P; Fauq A; Koo EH; Golde TE Nat Med; 2005 May; 11(5):545-50. PubMed ID: 15834426 [TBL] [Abstract][Full Text] [Related]
50. Disease-modifying therapies in Alzheimer's disease: how far have we come? Hüll M; Berger M; Heneka M Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302 [TBL] [Abstract][Full Text] [Related]
52. Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase. Tan Y; Zhang Q; Wong SG; Hua Q Curr Top Med Chem; 2016; 16(5):549-57. PubMed ID: 26268329 [TBL] [Abstract][Full Text] [Related]
53. Therapeutic potential of gamma-secretase inhibitors and modulators. Imbimbo BP Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933 [TBL] [Abstract][Full Text] [Related]
54. In silico prediction and screening of gamma-secretase inhibitors by molecular descriptors and machine learning methods. Yang XG; Lv W; Chen YZ; Xue Y J Comput Chem; 2010 Apr; 31(6):1249-58. PubMed ID: 19847781 [TBL] [Abstract][Full Text] [Related]
55. Alzheimer's disease drug development based on Computer-Aided Drug Design. Zeng H; Wu X Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837 [TBL] [Abstract][Full Text] [Related]
57. Computational insights into the development of novel therapeutic strategies for Alzheimer's disease. Prabhakar R Future Med Chem; 2009 Apr; 1(1):119-35. PubMed ID: 21426072 [TBL] [Abstract][Full Text] [Related]